rimeporide experimental drug treatment duchenne muscular dystrophy developed esperare granted orphan drug status european medicines substance blocks ion pump called antiporter exact mechanism unknown speculated inhibition pump reduces ph sodium calcium overload cells patients duchenne muscular rimeporide designed treatment chronic heart failure tested seven phase studies clinical trials patients congestive heart failure degree renal insufficiency subsequently drug licensed esperare swiss nonprofit aims repositioning drugs rare diseases may substance demonstrated efficacy several animal models duchenne muscular also recently tested young boys duchenne muscular dystrophy aged httpsenwikipediaorgwikirimeporide